Once-daily, subcutaneous administration of fondaparinux without monitoring is at least as effective and is as safe as adjusted-dose, intravenous administration of unfractionated heparin in the ...

Overview: Heparin is a blood thinner that is used to prevent or treat blood clots. It may be injected under the skin or into a blood vessel. The most common side effects are irritation at the ...

The pharmacodynamics of i.v. and subcutaneous (s.c.) tinzaparin sodium compared with heparin in healthy volunteers were studied. A randomized, open-label, five-treatment, five-period-crossover ...

Subcutaneous injections of unfractionated heparin are equally effective as subcutaneous low-molecular-weight heparin injections for preventing venous thromboembolism recurrence, a randomized study ...

Unfractionated heparin is often used as adjunctive therapy ... 30-mg intravenous bolus followed 15 minutes later by a subcutaneous injection of 1.0 mg per kilogram, with injections administered ...

Subcutaneous injections of the original form of the anticoagulant medication heparin is as effective and safe as subcutaneous administration of the newer and more expensive low-molecularweight heparin ...

Diagnosis Protein-losing enteropathy. Management Infusion of albumin followed by intravenous and subcutaneous therapy with unfractionated heparin. You have full access to this article via your ...

Heparin is available in the form of an injection to be administered either by intravenous or subcutaneous routes. Heparin can be used alone or sometimes can be combined with aspirin. Read the ...

Background: Little is known about the incidence and causes of heparin-induced skin lesions. The 2 most commonly reported causes of heparin-induced skin lesions are immune-mediated heparin-induced ...

BALTIMORE — Thousands of miles from a manufacturing plant in China, where the key active ingredient in heparin is sourced, Wanda Crowell receives a daily infusion of the drug in her bed at Johns ...

The pharmacodynamics of tinzaparin 4500 IU s.c. (treatment E) and s.c. heparin (treatment A) are compared in Figure 4. Intersubject variability for tinzaparin AUAC 0-t and AUAC 0- (16-27% ...